Interventions to Improve HPV Vaccine Uptake: A Systematic Review

Emily B. Walling, MD, MPHSc, Nicole Benzoni, MPHSc, Jarrod Dornfeld, MD, MPHSc, Rusha Bhandari, MD, Bryan A. Sisk, MD, Jane Garbutt, MBChB, Graham Colditz, DrPH, MD, MPH

CONTEXT: The human papillomavirus (HPV) vaccine is a safe, effective cancer prevention method that is underutilized in the United States. Despite increased understanding of barriers to vaccination, rates remain low. Globally, developed and developing nations have achieved high rates of vaccination.

OBJECTIVE: Identification of effective strategies is necessary to optimize uptake of the HPV vaccine. We systematically reviewed the literature for national and international interventions that have successfully increased HPV vaccine uptake.

DATA SOURCES: We used a standardized protocol to search for articles published between January 1, 2006, and April 30, 2015, in 3 electronic databases: PubMed, Scopus, and Embase.

STUDY SELECTION: We identified interventions designed to increase HPV vaccine uptake among adolescents and young adults aged 11 to 26 years. All study designs were acceptable. Only articles that included postintervention vaccination rates were included.

DATA EXTRACTION: Two authors independently reviewed each article for data extraction and quality assessment. Interventions were classified according to the Community Preventive Service Task Force guide.

RESULTS: Results were reported according to the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework. Fifty-one articles met eligibility criteria: 2 informational interventions, 18 behavioral interventions, and 31 environmental interventions. Factors associated with HPV vaccine uptake were increased vaccine availability, decreased financial barriers, and interventions targeting both providers and patients.

LIMITATIONS: Lack of consistent RE-AIM metric reporting, limiting our ability to assess intervention validity and quality.

CONCLUSIONS: Population-based vaccination strategies that increased vaccine availability reached the greatest number of adolescents and were most successful in achieving high rates of vaccination.

Dr Walling conceptualized the review, developed the search criteria, determined manuscript eligibility, extracted and interpreted the data, and drafted the manuscript. Ms Benzoni developed the search criteria, designed the data extraction instrument, determined manuscript eligibility, extracted the data reviewed, and revised the manuscript. Dr Dornfeld developed the search criteria, determined manuscript eligibility, extracted data, and reviewed and revised the manuscript. Drs Bhandari and Sisk extracted the data and reviewed and revised the manuscript. Dr Garbutt served as a senior advisor, assisted in data interpretation, and oversaw manuscript revisions. Dr Colditz served as senior advisor and assisted in data interpretation, and all authors approved the final manuscript as submitted.

Human papillomavirus (HPV) leads to ~600 000 new cases annually of cervical and genitourinary cancer worldwide, 26 900 of which occur in the United States.1,2 A 3-dose quadrivalent recombinant HPV vaccine (HPVV) has been available globally since 2006, recommended by the World Health Organization and the Centers for Disease Control and Prevention3,4 for girls aged 9 to 26 and extended to boys in 2011. Worldwide vaccination uptake at a rate of 80% would prevent an estimated two-thirds of new cases of cervical cancer.3

Despite a nearly 10-year record of safety and efficacy,5,6 vaccination rates in the United States remain low. On average, 60% of girls 13 to 17 years of age initiate the series, and 39.7% receive all 3 doses; only 41.7% of boys initiate and 21.6% complete the series. Wide variation in coverage is observed both within and between states.7 Underuse of HPVV is concerning: the majority of adolescents in the United States are missing an opportunity to prevent cancer later in life. Furthermore, a clear racial disparity associated with cervical cancer exists in the United States, African American women are more likely to be diagnosed at later disease stages and die at nearly twice the rate compared with non-Hispanic white women.8 This may be due to compromised access to secondary cancer screening and prevention services later in life,9 underscoring the necessity of primary prevention.

Multiple interventions to address poor vaccination rates have increased knowledge of HPV-related diseases and the HPVV.10–18 Although vaccination intent was increased, it was neither sustained nor translated into vaccination behavior. Furthermore, there has been speculation that parents from different ethnic and socioeconomic groups may face different barriers to vaccination and thus require different intervention strategies.17,19

Recent systematic reviews examining interventions to increase HPVV uptake have conflicting conclusions. Fu et al reviewed 33 articles describing educational interventions and concluded that no specific strategy merited recommendation.20 However, the included studies did not consistently report postintervention vaccination rates, complicating interpretation of intervention success. Nicolai et al reviewed 14 community and clinic interventions and found several successes.21 The authors acknowledged that far greater numbers could be reached if interventions were implemented on a larger scale. Furthermore, the relative success of many of these interventions fell short of national averages and stated vaccination goals.

Other countries have considerably more success achieving high rates of HPV vaccination.1 To gain insight from global efforts, we conducted a systematic review of the literature for national and international initiatives to increase HPV vaccination.

METHODS

This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA; see Supplemental Table 6) guidelines,22 posing the question: “What interventions have successfully achieved high rates of HPV vaccination in men and women 11 to 26 years old?”

Inclusion and Exclusion Criteria

Eligibility criteria are outlined in Table 1. Only articles including postintervention HPVV vaccination rates were included. Multiple articles describing the same intervention were excluded unless new data over a different time period was presented, allowing assessment of intervention sustainability.

### TABLE 1 Eligibility Criteria

<table>
<thead>
<tr>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design: any</td>
<td>Postintervention HPV vaccination rates not reported</td>
</tr>
<tr>
<td>Participants: men and/or women 11–26 y old</td>
<td>No original data (exception made for articles describing government interventions)</td>
</tr>
<tr>
<td>Intervention: to increase HPVV uptake</td>
<td>Abstract or research communication report only</td>
</tr>
<tr>
<td>Outcome: postintervention HPV vaccination rate reported</td>
<td>Population &lt;11 or &gt;26 y old</td>
</tr>
<tr>
<td>Study not available in English</td>
<td></td>
</tr>
</tbody>
</table>

Search Strategy

Search criteria were developed with the assistance of a medical librarian and conducted using 3 medical literature websites (PubMed, Scopus, and Embase) for articles published between January 1, 2006, and April 30, 2015 (Supplemental Information). One author (EW) scanned the bibliographies of included trials for articles missed by the original search, resulting in 51 eligible articles (Supplemental Figure 1).

Data Classification and Quality Assessment

The Community Guide’s Data Abstraction (CGDA) framework from the Community Preventive Service Task Force23 was used to guide data extraction and synthesis (Table 2 and 3). The Task Force identifies successful health interventions by conducting systematic reviews and provides a framework to assess an intervention’s design and execution. One author (NB) created a modified version of the CGDA, and 2 authors independently extracted data from each article using this tool.

A modified RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) model was used to evaluate quality and external validity.24–27 Metrics captured in this review are included in Table 4.
RESULTS

Results are reported according to the modified RE-AIM framework (Table 4, Supplemental Table 5).

Quality Assessment

Forty-nine articles described at least 1 element of all measured RE-AIM metrics. All articles described the intervention’s reach. Twenty-two articles did not describe barriers to implementation. Two articles did not include maintenance metrics. Several articles commented on barriers specific to public perception of the HPVV: lack of HPV knowledge, negative media surrounding the HPVV, and HPV safety concerns. Although not specific to intervention implementation, authors postulated these challenges likely compromised overall success of the intervention. Efficacy measures were heterogeneous, including rates of HPVV initiation (receipt of dose 1), completion (receipt of 3 doses), receipt of any dose as well as hazard, and risk ratio of receiving the vaccine. Vaccination results were determined from record review, interview, and by survey or self-report of patients or parents.

Reach

There was considerable variation in the number of participants reached by an intervention. In general, environmental interventions had the largest scope, consistently reaching >100 000 adolescents, whereas behavioral interventions reached as few as 37 adolescents. Provider and patient targeted interventions were an exception, often reaching several thousand and in 1 case >100 000 adolescents. A county-wide information intervention reached ~19 842 adolescents. Interventions overwhelmingly targeted girls; 9 targeted both genders and 1 targeted only boys. Four interventions targeted a specific vulnerable population.

Efficacy, Adoption/Implementation, and Maintenance

Informational Interventions (n = 2)

An intervention in the United States targeted low-income parents and provided HPV education, resulting in higher rates of series completion compared with preintervention (58% vs 42%). A community-wide media information campaign in the United States targeting adolescent boys resulted in higher rates of HPV vaccination in the exposed community during the media campaign compared with the control community (hazard ratio 1.34). The intervention was financially feasible, but there was no significant difference between case and control groups in the postintervention period.

Behavioral Interventions: Patient Targeted Decision Support (n = 5)

An intervention at an Australia university examined the effect of different informational material: a pamphlet emphasizing HPVV cervical cancer and genital wart prevention versus a pamphlet emphasizing HPVV cervical cancer prevention. Two months postintervention, the women who received the pamphlet emphasizing both cervical cancer and...
genital wart prevention had higher self-reported vaccination rates (42% vs 33%). However, response rate was low (54%), increasing the potential for bias. Hopfer et al demonstrated that female university students in the United States shown an HPV education video narrated by a peer and an expert had significantly higher vaccination rates compared with the control group (21.8% vs 11.8%). An intervention based in US school health clinics tested health message framing. Although intent to vaccinate increased, no effect on actual behavior was observed at the 10-month follow-up. Similarly, Wegwarth et al found that students at a German school randomized to receive an evidence-based “balanced” leaflet versus those randomized to a sensationalist “unbalanced” leaflet had improved understanding of the HPV but no difference in vaccination behavior. Finally, an intervention comparing the impact of using gain- or loss-framed messages among university students in the United States and found no effect on vaccine behavior.

Behavioral Interventions: Patient-Targeted Reminder Interventions (n = 7)

Four studies included randomization: Szilagyi et al described a tiered intervention escalating from telephone and letter reminders to home visits with the goal of increasing immunizations (including HPV and preventative care visits. They found significantly higher rates of vaccine initiation (58.5% vs 42.9%) and completion (36.5% vs 24.1%) in the intervention versus the control group. These researchers later examined an intervention that randomized patients to receive a letter, telephone call reminder, or standard of care. They found improved vaccination rates among those who received reminders but no significant difference based on modality. Chao et al demonstrated increased HPV completion rates among participants randomized to receive reminder letters versus standard of care (56.4% vs 46.6%). Both investigators identified a lack of reliable contact information as a barrier to implementation. Another trial randomized patients to receive telephone and mail reminders versus standard of care and showed significantly higher initiation (26.5% vs 15.3%) and completion rates (11.4% vs 4.4%) among the intervention group. Two interventions used text message reminders; both showed significantly higher rates in the intervention group (51.6% vs 35%) and (16% vs 5%). Challenges included variable clinic adherence to intervention procedures and participants forgetting to opt in to receive reminders, a barrier recognized and rectified early in the process. Authors commented on the financial feasibility and acceptability by parents of reminder interventions.

Behavioral Interventions: Provider-Targeted Interventions (n = 4)

Several interventions used a version of the Centers for Disease Control and Prevention–endorsed Assessment/Feedback/Incentive/Exchange (AFX) approach. Perkins et al compared HPV vaccination rates at clinics randomized to the AFX approach versus control clinics and demonstrated significantly increased HPV uptake, most impressively among boys. Gilkey et al randomized 91 clinics to 3 groups: in-person AFX consultation, webinar AFX consultation, or control. HPV completion rates were highest among clinics that received an in-person AFX consult. Both authors commented on the high level of acceptability of the intervention by key stakeholders. Moss et al observed a small but statistically significant increase in series completion rates after a 1-time AFX consultation over 1 month. Lastly, an intervention including electronic medical record prompts of patients overdue for the HPV did not increase vaccination rates during the intervention period. Inaccurate vaccine tracking resulting in missed vaccination opportunities were cited as potential barriers to intervention success.

Behavioral Interventions: Patient- and Provider-Targeted Interventions (n = 2)

Fiks et al described a multifaceted intervention randomizing clinics to 1 of 4 arms: family-focused reminders, clinician-focused reminders and education, a combined approach, or control. The combined arm had the highest rates of vaccination initiation and completion (25% and 76%, respectively) compared with control (16% and 63%). Authors described financial feasibility of the 12-month intervention period. An approach that included patient-focused education and telephone reminders with physician alerts and a script to address parents concerns resulted in 62.5% completion, representing a nearly 10-fold increase compared with the control group. Authors commented that implementation of the program was simple and parents welcomed the information.

Environmental Interventions (n = 31)

Barriers to implementation at all policy levels included the following: obtaining vaccination consent, reaching adolescents not in school, and reaching underserved areas.

Environmental Interventions: Small Policy (n = 12)

Five school-based vaccination programs (VP) were identified. A feasibility trial for the upcoming government-funded program in England had high rates of HPV initiation after the first year (70.6%), despite challenges with vaccine
delivery and multiple missed appointments.\textsuperscript{57} Programs in Brazil and South Africa included education campaigns and free vaccination, demonstrating uptake rates of 85\%\textsuperscript{64} (completion) and 58.6\%\textsuperscript{56} (at least 1 dose), respectively. Similar implementation challenges faced both programs: parents refusing to participate (up to 41\%)\textsuperscript{56} or not attending educational classes.\textsuperscript{56} Two school-based VPs in the United States included free HPVV.\textsuperscript{66,73} One summoned students to the health center for vaccination and demonstrated an initiation rate similar to national averages (59\%) but a dramatic improvement over the preintervention rate of 5\%. However, none of the students received all 3 doses. Still, the intervention was found to be cost-effective and accepted among those who agreed to participate.\textsuperscript{56} The second intervention included an HPVV education campaign and HPVV clinics at “host” schools, allowing students who attended control schools to receive vaccination at host schools. Researchers faced significant barriers including stipulations to vaccine administration, disparate implementation of the education campaign, and a low participation rate (2\%). Low initiation and completion rates were observed at host schools (6\% and 4.8\%, respectively), but initiation rates were higher than control schools (1\%). Authors noted that the intervention was financially feasible and parents who did participate were pleased with the intervention.\textsuperscript{73}

Four interventions set in clinics were identified. A feasibility trial in South Africa included an interview of parents and adolescents to assess HPVV acceptability and demonstrated a high completion rate (81.6\%).\textsuperscript{41} An intervention in Peru including cervical cancer screening of an older relative and free HPVV resulted in high rates of series completion (65\%), despite recruitment challenges and limited HPVV knowledge.\textsuperscript{50} Two interventions targeted specific vulnerable populations. Female sex workers in Cambodia received free HPVV, STD testing, reminders, and transportation to a health clinic, resulting in a series completion rate of 54\%.\textsuperscript{46} An intervention targeting rural, underserved women in the United States offered free HPVV and $25 compensation for answering a questionnaire. Less than half (44.9\%) of participants who signed consent received the first dose of the HPVV series. Implementation was challenged by inherent difficulties associated with reaching an underserved and undereducated population.\textsuperscript{75}

One intervention was set in both schools and clinics. A nationwide education campaign in Cameroon with reduced cost or free HPVV donated from the Merck patient assistance program resulted in an 84.6\% completion rate. Authors commented that the success of this intervention offered further support that school-based VPs were the most efficient method for delivery of HPVV in Africa.\textsuperscript{44}

Two interventions offering free HPVV were set in US universities. One compensated participants $10 for answering a questionnaire about HPV, resulting in vaccination rates similar to national averages (28.2\% series completion).\textsuperscript{42} An intervention supported by the Merck patient assistance program targeted underinsured students and included up to 3 reminder telephone calls. Although 100\% of participants initiated the vaccination series, only 48.3\% received 3 doses.\textsuperscript{78}

\textbf{Environmental Interventions: Big Policy, National Government Involvement (n = 12)}

Australia was the first country to institute a national HPV program and observed high completion rates at 1 and 5 years (77\% and 70\%, respectively). In addition to a school-based VP for 11- and 12-year-olds with catch-up for older students, there was early recognition of low rates of school attendance among indigenous populations, and efforts were made to increase HPVV availability in novel locations. Other challenges included HPVV safety concerns, obtaining parental consent, variable familiarity with school-based VPs, and variation in uptake across territories.\textsuperscript{52,58} Similarly, vaccination rates in Canada differed by province. Prince Edward Island had high rates after the sixth year of the school-based VP: 85\% and 79\% completion for girls and boys, respectively.\textsuperscript{48} In Ontario, vaccination completion rates increased annually over 3 years (51\%, 58\%, and 59\%). Implementation was challenged by a lack of a comprehensive vaccination strategy and several schools refused to participate.\textsuperscript{51} School-based VPs in Spain, Scotland, and Switzerland had high vaccination completion rates after 1 and 3 years of the ongoing programs (77.3\%, 81.0\%, and 61.4\%, respectively).\textsuperscript{47,54,72} Notably, developing countries also had high vaccination rates. A partnership between the Program for Appropriate Technology in Health, a nonprofit global health organization, and the governments of 4 countries using an education campaign and free HPVV at schools and clinics resulted in high completion rates in India (87.8\%), Peru (82.6\%), Uganda (88.9\%), and Vietnam (98.6\%).\textsuperscript{77} Likewise, a school-based VP in Rwanda had high rates of vaccine uptake after the first year of the program’s implementation (93.2\%).\textsuperscript{55} A program in the Netherlands was an exception to the widespread success of national school-based VPs, reporting HPVV initiation rates at 49.9\%. The authors questioned the quality of the education campaign and speculated that distrust of the HPVV among the local scientific community may have contributed to poor vaccination rates.\textsuperscript{53} Two clinic-based interventions offered free HPVV through national government programs. A program
in Italy included an education letter to parents and education of clinic staff. Dissatisfaction among parents and staff regarding the education was reported, and only 49.4% of the target population completed the HPVV series. In Denmark, the HPVV was incorporated into an existing vaccine program and accompanied by a nationwide education campaign, resulting in a completion rate of 62%. Environmental interventions, particularly school-based VP, had 2 major advantages that contributed to their success: increased access to the HPVV and ability to reach a large, diverse population, regardless of individual access to health care. Important themes emerged from descriptions of international school-based VP, which were widely accepted and welcomed by key stakeholders, including school personnel and parents. Location of HPV vaccination varied by age group; younger adolescents were more likely to receive vaccines at school, whereas older adolescents were more likely to go to their health care provider. Similarly, adolescents with poor school attendance had lower vaccination rates than those in school, underscoring the importance of convenience in modifying behavior. Finally, the success of environmental interventions in developing countries through school- and clinic-based vaccination programs illustrated that high vaccination coverage is not limited to high-income populations.

Environmental interventions, particularly school-based VP, had 2 major advantages that contributed to their success: increased access to the HPVV and ability to reach a large, diverse population, regardless of individual access to health care. Important themes emerged from descriptions of international school-based VP, which were widely accepted and welcomed by key stakeholders, including school personnel and parents. Location of HPV vaccination varied by age group; younger adolescents were more likely to receive vaccines at school, whereas older adolescents were more likely to go to their health care provider. Similarly, adolescents with poor school attendance had lower vaccination rates than those in school, underscoring the importance of convenience in modifying behavior. Finally, the success of environmental interventions in developing countries through school- and clinic-based vaccination programs illustrated that high vaccination coverage is not limited to high-income populations.

School-based VPs in the United States offered additional insight. An intervention in Colorado comparing schools with vaccination clinics to control schools demonstrated a higher risk ratio of receiving the HPV vaccine than the risk of receiving the other 2 adolescent vaccines offered, highlighting the importance of increased access and convenience needed to achieve HPVV coverage.

In support of this conclusion, an important observation by Stubbs et al was higher rates of initiation in “host” schools where vaccine clinics were located compared with “satellite” schools, again demonstrating the importance of increased availability. Additionally, although a small percentage of adolescents initiated the vaccine series, the majority of those who received the first dose of HPVV completed the series. This implies that with greater participation,
school-based VPs in the United States could achieve high HPVV completion rates and provide health care access for underserved populations. However, community support is vital for school-based VP to be successful. This may in part explain the low participation in school-based VP in the United States compared with those abroad. The relative novelty of school-based VP and differences in health care structures likely contribute to the disparate success.

Finally, it is worthwhile to note that cervical cancer does not carry the same widespread burden of morbidity and mortality in the United States as it does in developing countries. Worldwide, cervical cancer is the second most common cancer among women, and an overwhelming majority of deaths due to cervical cancer take place in developing countries. Perhaps these countries have a better appreciation of HPV-related disease and a greater sense of urgency to take advantage of the vaccine. These factors may contribute to greater uptake of HPVV internationally.

This study was strengthened by the wide scope of interventions and number of countries represented. This is simultaneously a limitation because the ability to generalize strategies to the United States may be compromised by local health care policy. The heterogeneity of the interventions affected our ability to assess quality. We initially planned to use the CGDA framework to assess quality; however, we ultimately determined that RE-AIM metrics were a better marker for intervention feasibility and sustainability. It became clear that traditional metrics of quality assessment captured by the CGDA, bias measures in particular, simply did not apply. For example, <2% of articles reported a participation rate, and only 1 study reported the attrition rate. Moreover, for nationwide vaccination strategies, participation and attrition rates were not applicable. The heterogeneous reporting of outcomes complicated interpretation of success, making direct comparison difficult. Five interventions had self-reported results, likely introducing a reporting bias. Series completion rate was frequently reported based on the proportion of those who initiated the HPVV series, rather than using the total targeted population as reference. Preintervention vaccination rates were rarely included. This was less problematic in analysis of national government interventions because the intervention represented national access to the HPVV. Many studies lacked a control group, making it impossible to tell if observed changes in vaccination rates would have occurred over time in the absence of the intervention. Finally, omission of implementation barriers and maintenance metrics was unfortunate because these details are key to replicating or improving an intervention.

One consistent deficiency in nearly all studies was the lack of data on race/ethnicity and socioeconomic status reporting, making it difficult to elucidate trends to support the theory that participants from different backgrounds respond preferentially to certain interventions. Given the significant disparity in outcomes of HPV related diseases, it is imperative we develop a better understanding of the relationship between demographics and vaccination behavior. As demonstrated in this review, environmental interventions targeting underserved populations can be successful and should be employed to protect the most vulnerable adolescents.56,58,75,78

CONCLUSIONS

A concerted effort is necessary to optimize uptake of the HPVV among adolescents in the United States. Overall, this review supports the use of environmental interventions such as school-based VP. Environmental approaches consistently reached the greatest number of participants and achieved the highest vaccination rates. The remarkable success internationally of government-initiated HPVV programs should be used to inform and guide US policy. When population-based vaccination strategies are not feasible, we support multi-pronged interventions that target both the provider and the patient.

Finally, a known barrier to successful vaccination is the 3-dose requirement. Early evidence indicates that fewer than 3 doses may be protective.10 Adolescents in the United States may not be as undervaccinated as indicated by the current rate of HPVV completion; an estimated 50% of girls and 31% of boys have received 2 doses.82 Until further research validates this finding, we should continue to adhere to international and national recommendations.

ACKNOWLEDGMENTS

The authors thank Ross C. Brownson, PhD, for his expertise and guidance interpreting and reporting interventions according to the RE-AIM framework and medical librarian Angela Hardi, MLS, for her assistance developing the search criteria.

ABBREVIATIONS

AFFECT: Assessment/Feedback/Incentive/Exchange
CGDA: Community Guide Data Abstraction
HPV: human papillomavirus
HPVV: human papillomavirus vaccine
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis
RE-AIM: Reach, Effectiveness, Adoption, Implementation, Maintenance
VP: vaccination programs
REFERENCES


18. Gottvall M, Tydén T, Höglund AT, Larsson M. Knowledge of human papillomavirus among high school students can be increased by an educational intervention. Int J STD AIDS. 2010;21(8):558–562


49. Hayashi Y, Shimizu Y, Natsu S, Hanley S, Konno R. High HPV vaccination


63. Chadenier GMC, Colzani E, Faccini M, Borriello CR, Bonazzi C. Assessment of the first HPV vaccination campaign in two northern Italian health districts. *Vaccine*. 2011;29(26):4405–4408


77. LaMontagne DS, Barge S, Le NT, et al. Human papillomavirus vaccine delivery strategies that achieved high
coverage in low- and middle-income countries. *Bull World Health Organ.* 2011;89(11):821–830


81. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al; Costa Rica Vaccine Trial Study Group Authors; PATRICIA Study Group Authors; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. *Lancet Oncol.* 2015;16(7):775–786

Interventions to Improve HPV Vaccine Uptake: A Systematic Review
Emily B. Walling, Nicole Benzoni, Jarrod Dornfeld, Rusha Bhandari, Bryan A. Sisk, Jane Garbutt and Graham Colditz
Pediatrics 2016;138;
DOI: 10.1542/peds.2015-3863 originally published online June 13, 2016;

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://pediatrics.aappublications.org/content/138/1/e20153863">http://pediatrics.aappublications.org/content/138/1/e20153863</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at: <a href="http://pediatrics.aappublications.org/content/suppl/2016/06/10/peds.2015-3863.DCSupplemental">http://pediatrics.aappublications.org/content/suppl/2016/06/10/peds.2015-3863.DCSupplemental</a></td>
</tr>
<tr>
<td>References</td>
<td>This article cites 71 articles, 10 of which you can access for free at: <a href="http://pediatrics.aappublications.org/content/138/1/e20153863.full#ref-list-1">http://pediatrics.aappublications.org/content/138/1/e20153863.full#ref-list-1</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s): Hematology/Oncology <a href="http://classic.pediatrics.aappublications.org/cgi/collection/hematology/oncology_sub">http://classic.pediatrics.aappublications.org/cgi/collection/hematology/oncology_sub</a> Cancer/Neoplastic <a href="http://classic.pediatrics.aappublications.org/cgi/collection/cancer:neoplastic_sub">http://classic.pediatrics.aappublications.org/cgi/collection/cancer:neoplastic_sub</a> Infectious Disease <a href="http://classic.pediatrics.aappublications.org/cgi/collection/infectious_diseases_sub">http://classic.pediatrics.aappublications.org/cgi/collection/infectious_diseases_sub</a> Vaccine/Immunization <a href="http://classic.pediatrics.aappublications.org/cgi/collection/vaccine:immunization_sub">http://classic.pediatrics.aappublications.org/cgi/collection/vaccine:immunization_sub</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="https://shop.aap.org/licensing-permissions/">https://shop.aap.org/licensing-permissions/</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://classic.pediatrics.aappublications.org/content/reprints">http://classic.pediatrics.aappublications.org/content/reprints</a></td>
</tr>
</tbody>
</table>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN: .
Interventions to Improve HPV Vaccine Uptake: A Systematic Review
Emily B. Walling, Nicole Benzoni, Jarrod Dornfeld, Rusha Bhandari, Bryan A. Sisk, Jane Garbutt and Graham Colditz

*Pediatrics* 2016;138;
DOI: 10.1542/peds.2015-3863 originally published online June 13, 2016;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/138/1/e20153863